Clinical applications of molecular biomarkers in precision diagnosis and management of classical philadelphia chromosome-negative myeloproliferative neoplasms
10.3760/cma.j.cn114452-20250222-00098
- VernacularTitle:分子标志物在经典费城染色体阴性骨髓增殖性肿瘤精准诊疗中的临床应用进展
- Author:
Xiaotong MA
1
;
Ming GUAN
1
;
Zhiyuan WU
1
Author Information
1. 复旦大学附属华山医院检验科，上海 200040
- Publication Type:Journal Article
- Keywords:
Myeloproliferative disorders;
Molecular biomarkers;
Precision diagnosis;
Personalized therapy
- From:
Chinese Journal of Laboratory Medicine
2025;48(12):1608-1615
- CountryChina
- Language:Chinese
-
Abstract:
Classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) comprise a group of clonal disorders originating from hematopoietic stem cells, commonly characterized by thrombotic events, extramedullary hematopoiesis, and a propensity for malignant progression to myelofibrosis or acute leukemia. With the inclusion in the core diagnostic criteria, molecular biomarkers has exhibited applicational valus in multiple levels in the aspects of personalized therapy to subtype MPN, interpret phenotypic heterogeneity, and predict clinical outcomes. Molecular biomarkers are currently being applied in disease diagnosis, progression prediction, therapeutic strategy refinement, precision monitoring, familial MPN screening, and the development of emerging detection technologies, advancing the shift from fundamental MPN research to individualized clinical management.
